Skip to main content

Table 3 Secondary outcomes

From: The efficacy and safety of itopride in feeding intolerance of critically ill patients receiving enteral nutrition: a randomized, double-blind study

  Itopride (n = 35) Metoclopramide (n = 35) p-value
Daily volume (ml), mean (SD) 1180.63 (63.42) 1001.43 (70.955) 0.001*
EN VR %, day 1, mean (SD) 64.34 (14.20) 61.2 (15.52) 0.364*
EN VR %, day 7, mean (SD) 88.03 (9.32) 74.17 (13.67) 0.001*
Percent of change in EN VR between day 1, day 7, mean (SD) 42.32 (29.6) 26.76 (36.51) 0.003**
Energy (Kcal/day), mean (SD) 1551.43 (216.417) 1390.14 (126.098) 0.001*
Energy Ratio % 89.158 (14.63) 79.7 (9.397) 0.002*
Protein (g/day), mean (SD) 85 (8.135) 78 (8.419) 0.001*
Protein Ratio %, mean (SD) 94.83 (10.1) 84.2 (10.26) 0.01*
ICU LOS (days), mean (SD) 15.97 (3.47) 16.23 (2.34) 0.71*
  1. EN VR Entera nutrition volume ratio. ICU LOS ICU length of stay
  2. *Student t test
  3. ** Mann Whitney test